Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
GrafTech International Ltd. (NYSE: GTI) shares increased 7.58 percent to close at $10.36 a share Tuesday. The stock traded between $10.15 and $10.54 on volume of 2.62 million shares traded. Analysts at Goldman Sachs have recently initiated coverage on the company with a “buy” rating. Shares of GrafTech International have fallen approximately 8.0 percent year-to-date.
Find out more about GrafTech International including full access to the free equity report at:
www.RDInvesting.com/GTI
Intuitive Surgical, Inc. (NASDAQ: ISRG) shares declined 0.95 percent to close at $449.51 a share Tuesday. The stock traded between $443.48 and $455.90 on volume of 741,537 shares traded. Analysts at Cantor Fitzgerald have recently downgraded the company’s rating to “hold” from “buy”. Shares of Intuitive Surgical have gained approximately 17.0 percent year-to-date.
Find out more about Intuitive Surgical including full access to the free equity report at:
www.RDInvesting.com/ISRG
Plug Power Inc. (NASDAQ: PLUG) shares increased 14.95 percent to close at $6.69 a share Tuesday. The stock traded between $6.24 and $7.09 on volume of 121.34 million shares traded. Analysts at Cowen and Co. have recently raised its price target on the company to $5.50 a share from $5.00. Shares of Plug Power have gained approximately 330.0 percent year-to-date.
Find out more about Plug Power including full access to the free equity report at:
www.RDInvesting.com/PLUG
ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) shares increased 5.70 percent to close at $4.45 a share Tuesday. The stock traded between $4.20 and $4.79 on volume of 2.07 million shares traded. Analysts at Piper Jaffray have recently upgraded the company’s rating to “neutral” from “underweight”. Shares of ZIOPHARM Oncology have gained approximately 3.0 percent year-to-date.
Find out more about ZIOPHARM Oncology including full access to the free equity report at:
www.RDInvesting.com/ZIOP
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Research Driven Investing
[email protected]